纤维蛋白原浓缩物与冷沉淀用于肝移植术中低纤维蛋白原血症:随机试验方案(FIBCRYO-LT试验)
本研究为随机对照试验方案,计划于2025年12月至2026年6月在一家三级大学医院开展,纳入肝移植术中发生低纤维蛋白原血症(标准中心实验室纤维蛋白原<100 mg/dL或TEG6S™功能纤维蛋白原最大振幅<15 mm)并需补充纤维蛋白原的患者,1:1随机接受冷沉淀(C组)或纤维蛋白原浓缩物(L组)。主要结局为治疗时间(从下单到完成静脉给药的时长)的组间比较。
要点
- 肝移植术中低纤维蛋白原血症患者随机接受冷沉淀或纤维蛋白原浓缩物。
- 主要结局为从下单到完成静脉给药的治疗时间(T-time)。
- 次要结局包括围术期出血、输血需求、凝血指标、再手术、血栓栓塞并发症、死亡率等。
核心结论
- 若L组治疗时间显著缩短,将支持纤维蛋白原浓缩物策略在肝移植术中快速凝血管理方面的优越性。
研究设计与样本
- 随机对照试验方案,计划于2025年12月至2026年6月在一家三级大学医院开展。
- 纳入肝移植术中发生低纤维蛋白原血症需补充纤维蛋白原的患者,1:1随机分为冷沉淀组(C组)和纤维蛋白原浓缩物组(L组)。
关键数值与推荐
- 术中低纤维蛋白原血症定义为标准中心实验室血清纤维蛋白原<100 mg/dL或血栓弹力图(TEG6S™)枸橼酸化功能纤维蛋白原最大振幅<15 mm。
- 主要结局为治疗时间(T-time),即从下单冷沉淀或纤维蛋白原浓缩物到完成静脉给药的持续时间。
临床怎么用
- 该试验旨在比较两种纤维蛋白原补充策略在肝移植术中的给药速度,为术中快速凝血管理提供随机证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Lyophilized factor concentrates, such as fibrinogen concentrate (FC), are considered superior to frozen products, such as cryoprecipitate, due to their rapid availability. Unlike frozen products, lyophilized factor concentrates do not require thawing or ABO blood type cross-matching, which can be time-consuming. We compared the time required for goal-directed management of hypofibrinogenemia using two strategies during liver transplantation (LT): a conventional cryoprecipitate-based strategy versus a lyophilized fibrinogen concentrate (FC)-based strategy. METHODS: This randomized trial will be performed in a tertiary university hospital from December 2025 to June 2026. Patients undergoing liver transplantation (LT) who provide written informed consents and develop intraoperative coagulopathy requiring fibrinogen supplementation-defined as serum fibrinogen < 100 mg/dL in standard central lab (SCL) tests or citrated functional fibrinogen maximum amplitude < 15 mm on thromboelastography (TEG6S™)-will be enrolled and randomized (1:1) to receive either cryoprecipitate (Group- C) or fibrinogen concentrate (Group- L). The primary outcome is an inter-group comparison of the treatment time (T-time, the duration from ordering cryoprecipitate or fibrinogen concentrate (FC) to completing its intravenous administration). Secondary outcomes include perioperative bleeding, blood transfusion requirements, coagulation profiles, reoperation, thromboembolic complications, mortality, oxygenation profiles, fibrinolysis phenotypes, bleeding-related costs, and length of hospital stay. DISCUSSION: A significantly shorter T-time in Group-L would support the superiority of the factor concentrate-based strategy for prompt intraoperative coagulation management during liver transplantation (LT). Its rapidity could reduce bleeding, transfusion requirements, and transfusion-related complications, thereby improving perioperative outcomes. TRIAL REGISTRATION: This trial was registered on ClinicalTrials.gov with the registration number of NCT06144112 on November 16, 2023 ( https://classic. CLINICALTRIALS: gov/ct2/show/ NCT06144112).
引用
- Bang YJ, Oh CS, Lee DK, et al. Fibrinogen concentrates versus cryoprecipitate for intraoperative hypofibrinogenemia in liver transplantation: study protocol for a randomized trial (FIBCRYO-LT trial). Trials. 2026. PMID: 42243996. doi:10.1186/s13063-026-09805-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。